ArQule is a biopharmaceutical company engaged in the research and development of therapeutics to treat cancers and rare diseases. Co.'s clinical pipeline includes: ARQ 531, which is a reversible dual inhibitor of both wild type and C481S-mutant Bruton's tyrosine kinase for B-cell malignancies refractory to other therapeutic options; Miransertib, which is a selective inhibitor of protein kinase B (AKT) in combination with the hormonal therapy, anastrozole; ARQ 751, which is a selective inhibitor of AKT for solid tumors harboring AKT, phosphoinositide 3-kinase or phosphatase and tensin homolog (PTEN) mutations or that are PTEN null; and Derazantinib, which is a multi-kinase inhibitor. The ARQL average annual return 10 years is shown above.
The Average Annual Return on the ARQL average annual return 10 years page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ARQL average annual return 10 years or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ARQL average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Video: Don't Forget Dividends in Average Annual Return!
